Merit Medical Systems (NASDAQ:MMSI) Stock Rating Upgraded by Zacks Research

Merit Medical Systems (NASDAQ:MMSI) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Merit Medical Systems’ Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $3.73 EPS, Q1 2027 earnings at $0.88 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.01 EPS, Q4 2027 earnings at $1.10 EPS, FY2027 earnings at $4.01 EPS, Q1 2028 earnings at $0.95 EPS, Q2 2028 earnings at $1.11 EPS and FY2028 earnings at $4.32 EPS.

MMSI has been the subject of several other reports. Barrington Research set a $114.00 price objective on shares of Merit Medical Systems in a report on Friday, July 31st. Piper Sandler boosted their target price on shares of Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Wells Fargo & Company raised their price target on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lifted their price target on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Raymond James Financial reiterated an “outperform” rating and set a $100.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Merit Medical Systems currently has a consensus rating of “Moderate Buy” and an average target price of $100.00.

Merit Medical Systems Stock Down 0.6%

MMSI stock opened at $90.54 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of 37.41, a PEG ratio of 2.27 and a beta of 0.49. Merit Medical Systems has a fifty-two week low of $59.74 and a fifty-two week high of $94.75. The stock has a fifty day moving average of $78.85 and a 200-day moving average of $72.74.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. The business had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, equities research analysts predict that Merit Medical Systems will post 3.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Merit Medical Systems in the fourth quarter worth $25,000. Kilter Group LLC purchased a new position in Merit Medical Systems during the second quarter worth about $25,000. Torren Management LLC bought a new position in Merit Medical Systems in the 4th quarter worth about $38,000. Covestor Ltd raised its holdings in shares of Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 336 shares in the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Merit Medical Systems in the 3rd quarter valued at about $42,000. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth.
• Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion.
• Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering.
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact.
• Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.